Research programme: oral T-cell vaccines - VAXIMM

Drug Profile

Research programme: oral T-cell vaccines - VAXIMM

Alternative Names: VXM 04; VXM 06

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator VAXIMM
  • Class Cancer vaccines
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Dec 2016 Preclinical development is ongoing Germany
  • 01 Dec 2016 Pharmacodynamics data from a preclinical studies in cancer released by VAXIMM
  • 01 Dec 2016 VAXIMM plans clinical trials for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top